Success Metrics

Active Trials
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
5
83%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Not yet recruiting5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 25 (83.3%)
N/A1 (16.7%)

Trials by Status

recruiting117%
not_yet_recruiting583%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

NCT07472478
not_yet_recruitingphase_2

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

NCT07244965
recruitingphase_2

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

NCT06875076
not_yet_recruitingphase_2

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

NCT06814158
not_yet_recruitingnot_applicable

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

NCT06766591
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07472478Phase 2

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

Not Yet Recruiting
NCT07244965Phase 2

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

Not Yet Recruiting
NCT06875076Phase 2

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

Recruiting
NCT06814158Phase 2

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

Not Yet Recruiting
NCT06766591Not Applicable

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Not Yet Recruiting
NCT06750952Phase 2

Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6